Illinois Municipal Retirement Fund Boosts Holdings in Edwards Lifesciences Corporation $EW

Illinois Municipal Retirement Fund lifted its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 28.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,851 shares of the medical research company’s stock after purchasing an additional 8,884 shares during the period. Illinois Municipal Retirement Fund’s holdings in Edwards Lifesciences were worth $3,191,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in EW. Geneos Wealth Management Inc. grew its holdings in Edwards Lifesciences by 3.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 8,545 shares of the medical research company’s stock valued at $684,000 after purchasing an additional 254 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in Edwards Lifesciences by 29.3% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 16,646 shares of the medical research company’s stock worth $1,333,000 after buying an additional 3,768 shares in the last quarter. Sigma Planning Corp lifted its holdings in Edwards Lifesciences by 8.2% in the 1st quarter. Sigma Planning Corp now owns 3,806 shares of the medical research company’s stock worth $305,000 after buying an additional 288 shares in the last quarter. Checchi Capital Advisers LLC boosted its position in Edwards Lifesciences by 22.1% in the 1st quarter. Checchi Capital Advisers LLC now owns 4,511 shares of the medical research company’s stock valued at $361,000 after buying an additional 815 shares during the last quarter. Finally, Nwam LLC boosted its position in Edwards Lifesciences by 2.8% in the 1st quarter. Nwam LLC now owns 32,909 shares of the medical research company’s stock valued at $2,635,000 after buying an additional 904 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the transaction, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $91.70, for a total value of $56,762.30. Following the transaction, the vice president owned 40,034 shares in the company, valued at $3,671,117.80. This trade represents a 1.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 45,577 shares of company stock valued at $3,855,527. Corporate insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Down 0.0%

NYSE:EW opened at $85.72 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The company has a market capitalization of $49.36 billion, a price-to-earnings ratio of 45.60, a price-to-earnings-growth ratio of 2.15 and a beta of 0.86. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The stock has a 50-day simple moving average of $87.34 and a 200 day simple moving average of $83.92.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. During the same quarter in the prior year, the firm posted $0.64 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Sell-side analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analyst Ratings Changes

EW has been the topic of a number of analyst reports. TD Cowen reaffirmed a “buy” rating and set a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a research report on Tuesday, June 2nd. Truist Financial increased their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a report on Thursday. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Evercore restated an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a report on Monday, July 6th. Finally, Robert W. Baird upped their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average target price of $98.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.